MiMedx Group (MDXG)
(Delayed Data from NSDQ)
$6.16 USD
-0.17 (-2.69%)
Updated Apr 18, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMMiMedx (MDXG) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$12.17 | $14.00 | $11.00 | 97.56% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for MiMedx comes to $12.17. The forecasts range from a low of $11.00 to a high of $14.00. The average price target represents an increase of 97.56% from the last closing price of $6.16.
Analyst Price Targets (6 )
Broker Rating
MiMedx currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, five are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/7/2024 | Lake Street Capital Markets | Brooks G O'Neil | Not Available | Strong Buy |
3/1/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Strong Buy | Strong Buy |
2/16/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Strong Buy |
1/5/2024 | Northland Capital Markets | Carl Byrnes | Strong Buy | Strong Buy |
10/27/2023 | Craig-Hallum | Chase Knickerbocker | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 5 |
Average Target Price | $12.17 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | 0.04 |